This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Chiesi hits the acquisition trail again. Will buy US speciality pharma company Cornerstone. ... Italy's Chiesi has signed its second acquisition deal in as many months, agreeing a $9.50-a-share deal for US speciality pharma company Cornerstone
US pharma company Cornerstone Therapeutics suffered a setback after an FDA advisory committee voted against approval of lixivaptan, the firm's drug candidate for hyponatremia or low sodium levels in the ... It was originally developed by Wyeth and
This can effectively kill a deal and potentially the product. Another example of a product acquisition is InterMune's sale of its approved product, Actimmune (interferon gamma-1b), to Vidara Therapeutics ... NCEs for respiratory disease. 212. EKR
Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics, respectively.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...